SCHEMBL200660

SCHEMBL200660

O=C1C=C[N]C=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzoquinone SCHEMBL3208089 0.69
Benzoquinone SCHEMBL18103 0.69
Benzoquinone SCHEMBL30679171 0.69
Benzoquinone SCHEMBL460082 0.69 ALDH1A1 (1.00)
Benzoquinone SCHEMBL10506648 0.69 ALDH1A1 (1.00)
Benzoquinone SCHEMBL5308519 0.69 ALDH1A1 (1.00)
Benzoquinone SCHEMBL1873085 0.65
Benzoquinone SCHEMBL3394588 0.65
Benzoquinone SCHEMBL10776546 0.65
Benzoquinone SCHEMBL6846712 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1951 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024067465-A1 KIF18A INHIBITOR 山东轩竹医药科技有限公司 2024-04-04 WO claimed
US-20240101576-A1 HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER ANTARES THERAPEUTICS, INC. 2024-03-28 US claimed
WO-2024032661-A1 KIF18A INHIBITOR AND USE THEREOF 山东轩竹医药科技有限公司 2024-02-15 WO claimed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 WO claimed
CN-117355532-A Tri-fused ring USP1 inhibitors and uses thereof 山东轩竹医药科技有限公司 2024-01-05 CN claimed
CN-117337290-A Tri-ring ubiquitin-specific protease 1 inhibitors and uses thereof 山东轩竹医药科技有限公司 2024-01-02 CN claimed
CN-117024319-A Amide compound, pharmaceutical composition containing same, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-11-10 CN claimed
CN-116981667-A Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment 蝎子疗法股份有限公司 2023-10-31 CN claimed
WO-2023183601-A1 METHODS OF SYNTHESIZING EGFR INHIBITORS SCORPION THERAPEUTICS, INC. (US) 2023-09-28 WO claimed
CN-116731022-A Tri-ring ubiquitin-specific protease 1 inhibitors and uses thereof 轩竹生物科技股份有限公司 2023-09-12 CN claimed
EP-0350691-A2 Heterocyclically substituted alpha-aryl-acrylic-acid esters, and fungicides containing these compounds BASF Aktiengesellschaft (DE) 1990-01-17 EP claimed
WO-1989010925-A1 NOVEL COMPOUNDS AND TREATMENT BEECHAM GROUP PLC (GB) 1989-11-16 WO claimed
EP-0064740-B1 CEPHALOSPORIN DERIVATIVES, AND PROCESS FOR THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1986-04-09 EP claimed
EP-0034759-B1 CHROMOGEN CEPHALOSPORINS AND PROCESS FOR THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1986-01-02 EP claimed
EP-0135142-A2 Cephalosporin derivatives and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1985-03-27 EP claimed
US-4448880-A Detection of β-lactamase utilizing a chromophoric cephalosporin composition HOECHST AG. (DE) 1984-05-15 US claimed
EP-0088320-A2 Cephalosporin derivatives and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1983-09-14 EP claimed
EP-0064740-A2 Cephalosporin derivatives, and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1982-11-17 EP claimed
US-4353824-A DETECTORS OF BETA-LACTAMASES HOECHST AKTIENGESELLSCHAFT (DE) 1982-10-12 US claimed
US-4312873-A FUNGICIDES SYNTEX (U.S.A.) INC. (US) 1982-01-26 US claimed